Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions
Masitinib, a selective tyrosine kinase inhibitor, was investigated as a radiosensitizer in three primary feline injection-site sarcoma (ISS) cell lines. Sensitivity to masitinib was previously assessed via cell growth inhibition assays with mean IC50 values of 5.5–8.6μM. Clonogenic assays were perfo...
Gespeichert in:
| Veröffentlicht in: | Research in veterinary science 2014-04, Vol.96 (2), p.304-307 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 307 |
|---|---|
| container_issue | 2 |
| container_start_page | 304 |
| container_title | Research in veterinary science |
| container_volume | 96 |
| creator | Turek, M. Gogal, R. Saba, C. Vandenplas, M.L. Hill, J. Feldhausser, B. Lawrence, J. |
| description | Masitinib, a selective tyrosine kinase inhibitor, was investigated as a radiosensitizer in three primary feline injection-site sarcoma (ISS) cell lines. Sensitivity to masitinib was previously assessed via cell growth inhibition assays with mean IC50 values of 5.5–8.6μM. Clonogenic assays were performed to determine the effect of masitinib and radiation on cell survival. Single dose radiation (0–12Gy) experiments were carried out under normal growth conditions in control ISS cells and in cells incubated with 1 or 6μM masitinib for 72h prior to irradiation. Radiation administered either alone or in combination with masitinib induced a dose-dependent reduction in clonogenic survival. Survival from the combined masitinib and radiation treatment was not significantly different from that of radiation alone. Results suggest that masitinib does not directly enhance ISS cell radiosensitivity under normal in vitro conditions, although this does not preclude the utility of further investigations to assess sensitization properties under altered conditions. |
| doi_str_mv | 10.1016/j.rvsc.2014.02.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1687692270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0034528814000356</els_id><sourcerecordid>1511393095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-e9336b8093004ed22d33acaec03cecc580a14954dec47ffa519123064b631c0b3</originalsourceid><addsrcrecordid>eNqFkc1u1DAURiMEotPCC7BAltiwSbj-iSeR2KAKKFIRG1hbjn3DOErsYjtTzUPwzjiawoIFrCzL5_t0r09VvaDQUKDyzdTEYzINAyoaYA0AfVTtaMtZzaSkj6sdABd1y7ruorpMaQIAQen-aXXBhATWU7mrfn7WyWXn3UAWTKdZZyQ2YCI-ZIL-oL1BktBv0NHlE8mBRG2dzi544jzJh4hIRpydx3Kf0GwvdeFLTkcTFk0MzjPZgERWbzGW8rjomXyP4T4fiAneui2VnlVPRj0nfP5wXlXfPrz_en1T3375-On63W1tBN3nGnvO5dBBz8tGaBmznGuj0QA3aEzbgaaib4VFI_bjqFvaU8ZBikFyamDgV9Xrc-9dDD9WTFktLm1Tao9hTYrKbi97xvbwf7SllJdB-ragr_5Cp7BGXxYpFPRCdG3LCsXOlIkhpYijuotu0fGkKKjNq5rU5lVtXhUwVbyW0MuH6nVY0P6J_BZZgLdnAMu3HR1GlYzDIs-6WJQoG9y_-n8BcOK15g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1509448552</pqid></control><display><type>article</type><title>Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Turek, M. ; Gogal, R. ; Saba, C. ; Vandenplas, M.L. ; Hill, J. ; Feldhausser, B. ; Lawrence, J.</creator><creatorcontrib>Turek, M. ; Gogal, R. ; Saba, C. ; Vandenplas, M.L. ; Hill, J. ; Feldhausser, B. ; Lawrence, J.</creatorcontrib><description>Masitinib, a selective tyrosine kinase inhibitor, was investigated as a radiosensitizer in three primary feline injection-site sarcoma (ISS) cell lines. Sensitivity to masitinib was previously assessed via cell growth inhibition assays with mean IC50 values of 5.5–8.6μM. Clonogenic assays were performed to determine the effect of masitinib and radiation on cell survival. Single dose radiation (0–12Gy) experiments were carried out under normal growth conditions in control ISS cells and in cells incubated with 1 or 6μM masitinib for 72h prior to irradiation. Radiation administered either alone or in combination with masitinib induced a dose-dependent reduction in clonogenic survival. Survival from the combined masitinib and radiation treatment was not significantly different from that of radiation alone. Results suggest that masitinib does not directly enhance ISS cell radiosensitivity under normal in vitro conditions, although this does not preclude the utility of further investigations to assess sensitization properties under altered conditions.</description><identifier>ISSN: 0034-5288</identifier><identifier>EISSN: 1532-2661</identifier><identifier>DOI: 10.1016/j.rvsc.2014.02.001</identifier><identifier>PMID: 24602916</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Apoptosis ; Cat ; Cat Diseases - radiotherapy ; Cats ; Cell Line, Tumor ; Cell Survival - drug effects ; Clonogenic ; Colonies & territories ; Dose-Response Relationship, Drug ; Drug dosages ; Masitinib ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Radiation ; Radiation therapy ; Radiation-Sensitizing Agents - pharmacology ; Radiation-Sensitizing Agents - therapeutic use ; Rodents ; Sarcoma ; Sarcoma - radiotherapy ; Sarcoma - veterinary ; Science ; Studies ; Thiazoles - pharmacology ; Thiazoles - therapeutic use ; Tyrosine kinase inhibitor ; Variance analysis ; Veterinary medicine</subject><ispartof>Research in veterinary science, 2014-04, Vol.96 (2), p.304-307</ispartof><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Apr 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-e9336b8093004ed22d33acaec03cecc580a14954dec47ffa519123064b631c0b3</citedby><cites>FETCH-LOGICAL-c417t-e9336b8093004ed22d33acaec03cecc580a14954dec47ffa519123064b631c0b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0034528814000356$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24602916$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turek, M.</creatorcontrib><creatorcontrib>Gogal, R.</creatorcontrib><creatorcontrib>Saba, C.</creatorcontrib><creatorcontrib>Vandenplas, M.L.</creatorcontrib><creatorcontrib>Hill, J.</creatorcontrib><creatorcontrib>Feldhausser, B.</creatorcontrib><creatorcontrib>Lawrence, J.</creatorcontrib><title>Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions</title><title>Research in veterinary science</title><addtitle>Res Vet Sci</addtitle><description>Masitinib, a selective tyrosine kinase inhibitor, was investigated as a radiosensitizer in three primary feline injection-site sarcoma (ISS) cell lines. Sensitivity to masitinib was previously assessed via cell growth inhibition assays with mean IC50 values of 5.5–8.6μM. Clonogenic assays were performed to determine the effect of masitinib and radiation on cell survival. Single dose radiation (0–12Gy) experiments were carried out under normal growth conditions in control ISS cells and in cells incubated with 1 or 6μM masitinib for 72h prior to irradiation. Radiation administered either alone or in combination with masitinib induced a dose-dependent reduction in clonogenic survival. Survival from the combined masitinib and radiation treatment was not significantly different from that of radiation alone. Results suggest that masitinib does not directly enhance ISS cell radiosensitivity under normal in vitro conditions, although this does not preclude the utility of further investigations to assess sensitization properties under altered conditions.</description><subject>Animals</subject><subject>Apoptosis</subject><subject>Cat</subject><subject>Cat Diseases - radiotherapy</subject><subject>Cats</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Clonogenic</subject><subject>Colonies & territories</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug dosages</subject><subject>Masitinib</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Radiation-Sensitizing Agents - pharmacology</subject><subject>Radiation-Sensitizing Agents - therapeutic use</subject><subject>Rodents</subject><subject>Sarcoma</subject><subject>Sarcoma - radiotherapy</subject><subject>Sarcoma - veterinary</subject><subject>Science</subject><subject>Studies</subject><subject>Thiazoles - pharmacology</subject><subject>Thiazoles - therapeutic use</subject><subject>Tyrosine kinase inhibitor</subject><subject>Variance analysis</subject><subject>Veterinary medicine</subject><issn>0034-5288</issn><issn>1532-2661</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAURiMEotPCC7BAltiwSbj-iSeR2KAKKFIRG1hbjn3DOErsYjtTzUPwzjiawoIFrCzL5_t0r09VvaDQUKDyzdTEYzINAyoaYA0AfVTtaMtZzaSkj6sdABd1y7ruorpMaQIAQen-aXXBhATWU7mrfn7WyWXn3UAWTKdZZyQ2YCI-ZIL-oL1BktBv0NHlE8mBRG2dzi544jzJh4hIRpydx3Kf0GwvdeFLTkcTFk0MzjPZgERWbzGW8rjomXyP4T4fiAneui2VnlVPRj0nfP5wXlXfPrz_en1T3375-On63W1tBN3nGnvO5dBBz8tGaBmznGuj0QA3aEzbgaaib4VFI_bjqFvaU8ZBikFyamDgV9Xrc-9dDD9WTFktLm1Tao9hTYrKbi97xvbwf7SllJdB-ragr_5Cp7BGXxYpFPRCdG3LCsXOlIkhpYijuotu0fGkKKjNq5rU5lVtXhUwVbyW0MuH6nVY0P6J_BZZgLdnAMu3HR1GlYzDIs-6WJQoG9y_-n8BcOK15g</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Turek, M.</creator><creator>Gogal, R.</creator><creator>Saba, C.</creator><creator>Vandenplas, M.L.</creator><creator>Hill, J.</creator><creator>Feldhausser, B.</creator><creator>Lawrence, J.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20140401</creationdate><title>Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions</title><author>Turek, M. ; Gogal, R. ; Saba, C. ; Vandenplas, M.L. ; Hill, J. ; Feldhausser, B. ; Lawrence, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-e9336b8093004ed22d33acaec03cecc580a14954dec47ffa519123064b631c0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>Cat</topic><topic>Cat Diseases - radiotherapy</topic><topic>Cats</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Clonogenic</topic><topic>Colonies & territories</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug dosages</topic><topic>Masitinib</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Radiation-Sensitizing Agents - pharmacology</topic><topic>Radiation-Sensitizing Agents - therapeutic use</topic><topic>Rodents</topic><topic>Sarcoma</topic><topic>Sarcoma - radiotherapy</topic><topic>Sarcoma - veterinary</topic><topic>Science</topic><topic>Studies</topic><topic>Thiazoles - pharmacology</topic><topic>Thiazoles - therapeutic use</topic><topic>Tyrosine kinase inhibitor</topic><topic>Variance analysis</topic><topic>Veterinary medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turek, M.</creatorcontrib><creatorcontrib>Gogal, R.</creatorcontrib><creatorcontrib>Saba, C.</creatorcontrib><creatorcontrib>Vandenplas, M.L.</creatorcontrib><creatorcontrib>Hill, J.</creatorcontrib><creatorcontrib>Feldhausser, B.</creatorcontrib><creatorcontrib>Lawrence, J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Research in veterinary science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turek, M.</au><au>Gogal, R.</au><au>Saba, C.</au><au>Vandenplas, M.L.</au><au>Hill, J.</au><au>Feldhausser, B.</au><au>Lawrence, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions</atitle><jtitle>Research in veterinary science</jtitle><addtitle>Res Vet Sci</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>96</volume><issue>2</issue><spage>304</spage><epage>307</epage><pages>304-307</pages><issn>0034-5288</issn><eissn>1532-2661</eissn><abstract>Masitinib, a selective tyrosine kinase inhibitor, was investigated as a radiosensitizer in three primary feline injection-site sarcoma (ISS) cell lines. Sensitivity to masitinib was previously assessed via cell growth inhibition assays with mean IC50 values of 5.5–8.6μM. Clonogenic assays were performed to determine the effect of masitinib and radiation on cell survival. Single dose radiation (0–12Gy) experiments were carried out under normal growth conditions in control ISS cells and in cells incubated with 1 or 6μM masitinib for 72h prior to irradiation. Radiation administered either alone or in combination with masitinib induced a dose-dependent reduction in clonogenic survival. Survival from the combined masitinib and radiation treatment was not significantly different from that of radiation alone. Results suggest that masitinib does not directly enhance ISS cell radiosensitivity under normal in vitro conditions, although this does not preclude the utility of further investigations to assess sensitization properties under altered conditions.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24602916</pmid><doi>10.1016/j.rvsc.2014.02.001</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0034-5288 |
| ispartof | Research in veterinary science, 2014-04, Vol.96 (2), p.304-307 |
| issn | 0034-5288 1532-2661 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1687692270 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Apoptosis Cat Cat Diseases - radiotherapy Cats Cell Line, Tumor Cell Survival - drug effects Clonogenic Colonies & territories Dose-Response Relationship, Drug Drug dosages Masitinib Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Radiation Radiation therapy Radiation-Sensitizing Agents - pharmacology Radiation-Sensitizing Agents - therapeutic use Rodents Sarcoma Sarcoma - radiotherapy Sarcoma - veterinary Science Studies Thiazoles - pharmacology Thiazoles - therapeutic use Tyrosine kinase inhibitor Variance analysis Veterinary medicine |
| title | Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A12%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Masitinib%20mesylate%20does%20not%20enhance%20sensitivity%20to%20radiation%20in%20three%20feline%20injection-site%20sarcoma%20cell%20lines%20under%20normal%20growth%20conditions&rft.jtitle=Research%20in%20veterinary%20science&rft.au=Turek,%20M.&rft.date=2014-04-01&rft.volume=96&rft.issue=2&rft.spage=304&rft.epage=307&rft.pages=304-307&rft.issn=0034-5288&rft.eissn=1532-2661&rft_id=info:doi/10.1016/j.rvsc.2014.02.001&rft_dat=%3Cproquest_cross%3E1511393095%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1509448552&rft_id=info:pmid/24602916&rft_els_id=S0034528814000356&rfr_iscdi=true |